The agency said Friday that it approved a new indication for a drug marketed by Eli Lilly and Boehringer Ingelheim. » Read More
By: Elizabeth Gurdus
Kenneth Frazier, the CEO of pharmaceutical giant Merck, says Trump's call to revamp Obamacare could prove useful. » Read More
Shares of Bluebird were up more than 24 percent in premarket trade Thursday. » Read More
Novozymes CEO, Peder Holk Nielsen reflects upon the biotechnology firm’s latest earnings, which missed market expectations.
These innovative companies are working on new methods to make chemotherapy safer, and more tolerable, for cancer patients in America.
Mylan has raised prices of the anti-allergy device more than 500 percent in recent years.
Eli Lilly reported third-quarter revenue below Wall Street estimates, driven by lower demand for its products outside the United States.
Merck reported a 19.6 percent rise in net profit, driven primarily by higher demand for its new cancer drug Keytruda.
Mylan has been accused of underpaying Medicaid in rebates for EpiPens, and agreed to pay $465 million to the government to resolve such claims.
Stacey Gilbert, Susquehanna Capital Group and Eddy Elfenbein, "Crossing Wall Street" blog, discuss the biotech sector with Brian Sullivan.
CNBC's Meg Tirrell reports the latest on Alkermes' latest depression drug trial.
Alkermes' ALKS 5461 proved effective in treating patients with major depressive disorder that failed to benefit from other therapies.
CNBC's Meg Tirrell reports the latest surrounding Ariad Pharmaceuticals and the company's drug price hike.
CNBC's Meg Tirrell reports the latest on a tweet sent by Sen. Bernie Sanders about Ariad Pharmaceuticals' cancer drug pricing.
Sen. Bernie Sanders and Rep. Elijah Cummings request details after Ariad repeatedly raised the price of its drug.
The CEO of a leading biopharmaceutical company has tried to reassure investors over upcoming U.S. elections.
Actelion wants to create value in its industry and the best way is to innovate as well as discover and develop new drugs says CEO, Jean-Paul Clozel, when weighing in on potential M&A opportunities.
Actelion has raised its 2016 financial targets after posting core net income of 691 million Swiss francs for the first nine months. Chief Executive, Jean-Paul Clozel discusses the results.
Next month the U.S. will decide its future president. Actelion CEO, Jean-Paul Clozel discusses how concerned he is about the election and what each outcome would mean for pharmaceuticals.
Get the best of CNBC in your inbox